Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Pharmacol Res. 2017 Jun 17;123:10–25. doi: 10.1016/j.phrs.2017.06.008

Figure 6.

Figure 6

GNE-317 targets micro-metastases and dormant tumor cells. A, Subgroup analysis of GNE-317 treated metastases, separately for non-permeable micro- (n=10) and macro-metastases (n=6) (***, P < 0.001 and *, P=0.033; two- sided t tests). B–E, Treatment response of single, long-term, non-proliferating and non-regressing, thus dormant, melanoma cells. The single cells are slowly moving during dormancy. After start of treatment with GNE-317 at D31 (C), the dormant cells regressed within 8 days (E) (adapted from (Osswald et al. 2016), with permission). (2-column fitting image)